2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Imaging, Molecular Testing, Treatment Considerations, Therapy Sequence, Biological Therapies, Transplantation, Non-Biological Therapies, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Microbiome, Clinical Practice (Health Services and Quality), Clinical Guidelines, Value, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Immunology, GVHD, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Research, AML, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

6029 Gut microbiota imbalance in allogeneic HSCT recipients with post-transplant diarrhea: Insights from fecal metagenomic sequencing

Fengjiao Wang, Feng Gou2, Chunhui Xu3, Rongli Zhang4, Erlie Jiang, MD5
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 Guiqian International Hospital,Guizhou, Guizhou, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Background: Post-transplant diarrhea is a common complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Gut microbiota imbalance is a common feature of post-transplant diarrhea and frequently complicates both diagnostic evaluation and clinical management. We aimed to characterize gut microbiota imbalance and investigate the potential role of fecal metagenomic next-generation sequencing (mNGS) in the evaluation of allo-HSCT recipients with post-transplant diarrhea.
Methods: We retrospectively analyzed 56 allo-HSCT recipients with post-transplant diarrhea who underwent 91 fecal mNGS assessments. Clinical characteristics, microbiota profiles, treatment responses, and outcomes were evaluated.
Results: Among the 56 patients, gut microbiota imbalance was identified in 41 (73.2%) patients, with potential pathogenic bacteria detected in fecal samples. Of these,  34 (60.7%) had concurrent gastrointestinal graft-versus-host disease (GI GVHD) and gut microbiota imbalance, and 7 (12.5%) had gut dysbiosis alone. Patients with gut dysbiosis alone had favorable outcomes, whereas patients with concurrent GVHD and gut microbiota imbalance experienced high mortality. Fecal mNGS identified a broad spectrum of bacterial, fungal, viral, and parasitic pathogens, including uncommon organisms such as Trichosporon asahii and Elizabethkingia anophelis. Several patients subsequently developed extraintestinal dissemination of pathogens initially detected in stool samples. Among 44 patients who underwent both fecal mNGS and conventional culture, only 3 cultures yielded positive results, compared with pathogen detection in 41 patients by mNGS.
Conclusions: Fecal mNGS identified gut microbiota imbalance in allo-HSCT recipients and may contribute valuable information to the diagnostic assessment of post-transplant diarrhea. The high frequency of concurrent GVHD and gut dysbiosis highlights the importance of comprehensive diagnostic assessment to guide individualized management in this high-risk population.

Fengjiao Wang: No relevant conflicts of interest to declare.